{
  "pmcid": "12449959",
  "sha256": "988778e761504778bbd9aa3a601a5061c4b4ec1e7abbe44306343a0d5ee133e7",
  "timestamp_utc": "2025-11-09T23:39:12.848825+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.974060150375944,
    "reading_ease": 31.77532581453636,
    "word_count": 266
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Title: Randomised Controlled Trial Comparing Covered Stents and Drug-Coated Balloons in Femoropopliteal Artery Occlusion"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients were randomly assigned to receive either CS (n=94) or DCB (n=100) angioplasty."
      },
      "Participants": {
        "score": 2,
        "evidence": "194 patients with chronic total femoropopliteal occlusion were included from seven centers"
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients were randomly assigned to receive either CS (n=94) or DCB (n=100) angioplasty."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study aimed to evaluate the midterm efficacy of covered stents (CS) versus drug-coated balloons (DCB) in patients with femoropopliteal artery occlusion."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was primary patency at 24 months."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Patients were randomly assigned to receive either CS (n=94) or DCB (n=100) angioplasty."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "194 patients with chronic total femoropopliteal occlusion were included from seven centers between January 2020 and December 2022."
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The CS group showed significantly greater primary patency at 24 months compared to the DCB group (74.4% vs. 55.8%, p=0.019)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were similar between groups, with no significant differences in major adverse events, limb salvage, or overall survival rates."
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 1,
        "evidence": "The study was funded by the National Natural Science Foundation of China (No. 82370459)."
      }
    },
    "total_score": 17,
    "max_score": 25
  }
}